If you think this trial is relevant to your situation, please contact your Cancer Specialist to discuss further.
A Phase II trial of the histone deacetylase (HDAC) inhibitor sodium valproate with anti-EGFR monoclonal antibody maintenance in the first-line treatment of patients with RAS wild type metastatic colorectal cancer.
Purpose of the Study
Colorectal cancer is a major cause of cancer related deaths for which there is an urgent need to develop new treatments. The drug valproate has been to treat epilepsy and mood disorders for over 50 years. We have found that valproate can profoundly increase the anti-tumour activity of a class of drugs known as EGFR inhibitors in laboratory models of colon cancer. We will now test the activity of this drug combination in a phase II clinical trial in patients with advanced colon cancer.
Dr Fiona Chionh – email@example.com
DETAILED INFORMATION AVAILABLE
More detailed information to come.
Professor Niall Tebbutt
Professor John Mariadason
Dr Fiona Chionh
2020 Innovation Grant
MRFF Efficient Use of Existing Medicines 2020
If you think this clinical trial may be relevant to your patient or to discuss further, please contact the Clinical Trial team.